Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

  title={Covid-19: Novavax vaccine efficacy is 86\% against UK variant and 60\% against South African variant},
  author={Elisabeth Mahase},
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered threeweeks apart and reported 62 symptomatic cases of covid-19, of which 56 were in the placebo group (saline) and six in the vaccine group. Of the 62 cases, only one was severe (in the placebo group), and 32 were with the UK variant. 
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
This study reviews the most recent data of 12 vaccines to evaluate their efficacy, safety profile and usage in various populations to compare the protective efficacy and risks of vaccination for the global control of COVID-19 through herd immunity.
Review of: "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant"
The conclusions of the study are rather disappointing indicating that the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate COVID-19 caused by the B. 1.1.351 variant in South Africa.
Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review
Full vaccination (two doses) offers strong protection against Alpha (B.1.7) with 13 out of 15 studies reporting more than 84% efficacy, but the results are not conclusive against the Beta (B .1.351) variant.
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study
While single dose vaccination was not sufficiently protective, the two-dose dosing scheme of the inactivated vaccines was effective against the Delta variant infection in real-world settings, with the estimated efficacy exceeding the World Health Organization minimal threshold of 50%.
Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants
  • Satyendra Prakash
  • Medicine, Biology
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews
  • 2022
Vaccines against COVID-19 – Catching the Rays of Hope
This review aims to elucidate the status of vaccine candidates in advanced trials along with the vaccines, which have been granted emergency approvals, and their probability of efficacy against newer variants of the virus.
Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use
A massive vaccination drive would be needed to protect people of all ages and would require unprecedented coordination at the national and international levels for generating funds to purchase the required doses of vaccines, fair distribution of doses and managing the mechanics of delivering vaccines throughout the world.
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
There is a need to establish a unified evaluation standard of vaccine effectiveness, monitor vaccine safety and effectiveness, along with the virological characteristics of SARS-CoV-2 variants, and determine the most useful booster schedule.
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
A snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern are provided.
SARS-CoV-2 Mutations in Brazil: From Genomics to Clinical Conditions
Due to the high rate of transmissibility, Brazil became the new COVID-19 outbreak epicenter, being a reference region to monitor how SARS-CoV-2 is mutating and spreading. Here, we combined genomic